All News

hidradenitis.jpg

Higher Comorbidities in Hidradenitis Suppurativa

d Jack Cush, MD

JAMA Dermatology reports that patients with hidradenitis suppurativa have significantly more comorbidities than do patients with psoriasis.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – Eat Your Veggies (4.19.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Shoulder.jpg

Timing of Shoulder Injections Impacts Surgical Infection Risk

d Jack Cush, MD

A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.

Read Article
pills.jpg

Polypharmacy Blunts Responses and Ups the Safety Risks

d Jack Cush, MD

A study from the British Society for Rheumatology Biologics Register (BSRBR-RA) demonstrates that polypharmacy is a predictor of lower treatment responses and more serious adverse events (SAEs) in rheumatoid arthritis (RA) patients.

Read Article
lupus_0.jpg

EULAR 2019 Update to Lupus Management

d Jack Cush, MD

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Read Article
sclerodact.jpg

Mortality Risk Factors in Systemic Sclerosis

d Jack Cush, MD

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

Read Article
knee.injx_.lat_.jpg

Intraarticular Trans-Capsaicin Effective in Knee OA

d Jack Cush, MD

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

Read Article
knee2_0.JPG (keep)

Smoking Not Protective Against Knee OA

d RheumNow

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark.

Read Article
Namilumab (mono ab to GM-CSF, Granulocyte-macrophage colony-stimulating factor) with good efficacy among MTX/TNF inadequate responders in a phase II RCT. NNT = 3-4 at week 12 for ACR50 at max dose. Some respiratory ADE but nothing major. https://t.co/hwHDFqCqOq https://t.co/XPsc4fjsXx

Links:

Mike Putman EBRheum ( View Tweet)
Kuddos to Philip! https://t.co/WC1EcPcz4J

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is Up! Eat Your Veggies and more about drug prices, gout, tapering, PSS mortality, insoles, Temporal arter bx & more. https://t.co/3gmVISUv9E or listen to the podcast on iTunes or SoundCloud here>> https://t.co/URNYnLd7Yi

Links:

Dr. John Cush RheumNow ( View Tweet)

Meet The Lancet Rheumatology: Advisory Board https://t.co/fA0siCsQbX

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase 3 study tanezumab (anti-NGF) 2.5 mg or 5 mgin knee or hip OA find that 5 mg met 2/3 of 3 primary endpoints at 16wks; but the lower dose failed to be superior to NSAIDs in this 1 yr study. Safety outcomes where less favorable w/ tanezumab. https://t.co/l4Qffdn1nl

Links:

Dr. John Cush RheumNow ( View Tweet)

NXP-2 Abs Are associated with your metal myositis and a cancer risk but also associated with calcinosis. Rheumatology 2019; Mar 16 https://t.co/8qTmZpo6Cj
Dr. John Cush RheumNow ( View Tweet)
Comparing fibromyalgia, PsA, Psoriasis Pts - FM has more entheseal tenderness (92%) than PSA (66%) and PSO (59%). However with ultrasound, entheseal involvement were more frequent in PsA & psoriasis (~90%) vs FM (75%). What? US enthesitis in FM? https://t.co/wNBQEB3j0O

Links:

Dr. John Cush RheumNow ( View Tweet)

Lateral wedge insoles are often used medial knee OA. Study of 63 preselected pts shows a significant pain reduction (vs neutral soles) but mean difference was 0.7 on 0–10 scale; thus benefitting only a minority of pts https://t.co/7SK7Cl1Uft

Links:

Dr. John Cush RheumNow ( View Tweet)

TARA study takes 189 #RA pts in remission on combo Rx and tapers either the csDMARD or biologic. At 1 year, flare rates were similar 33% (DMARD) vs 43% (biologic). Tapering TNF inhibitors was superior, but would have saved more $$. https://t.co/XxZbx5zjCC

Links:

Dr. John Cush RheumNow ( View Tweet)

The price of new osteoporosis drug Evenity (romosuzumab; sclerostin inhibitor) is $1,825/mo. or $21,900/Yr; Just FDA approved for post-menopausal OP at high risk for Fx . Amgen estimates Evenity to be 34-74% lower than Tymlos & Forteo. https://t.co/lYHyukTRPw

Links:

Dr. John Cush RheumNow ( View Tweet)

Immunomonitoring with microarrays from the SLE PROMISE pregnancy study shows that adverse outcomes (preeclampsia) can be identified by quantifying plasma cell, interferon and neutrophil RNA levels during the pregnancy https://t.co/81cBGA3hKx.

Links:

Dr. John Cush RheumNow ( View Tweet)

Peripheral Nervous system involvement in lupus is uncommon at 6.9% - 1/3 were polyneuropathy, 1/3 were cranial neuropathy and few mononeuritis. Risk greatest with age, lupus disease activity and damage https://t.co/0JxhcrZQb1

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×